News | December 08, 2009

First U.K. Patients Implanted With Coronary Bifurcation Stent

December 8, 2009 – The first live U.K. cases involving Cappella’s self-expanding Sideguard Coronary Sidebranch Stent and delivery system were recently performed at PCI Live 2009 with the second case following immediately thereafter, off-camera.

Dr. Joseph D. Mills, consultant cardiologist at the Liverpool Heart and Chest Hospital, U.K., performed both procedures. “We see numerous bifurcation cases and are very pleased to see that there is now a dedicated and straightforward solution to treating complex bifurcation lesions,” Dr. Mills said. “As the first centre in the U.K. to use Sideguard, we are very satisfied with the results.”

Cappella recently added an additional size of 3.25 mm to their current portfolio of 2.5 and 2.75 mm stents. This now enables treatment of bifurcation lesions in lumen diameters from 2.25 to 3.25 mm and lesion lengths less than or equal to 7 mm.

The Sideguard focuses on treating the sidebranch of diseased coronary arteries first, rather than the main vessel. It allows the preferred stent of choice for the main vessel. The stent offers an optimal design specific to the anatomy of the sidebranch, combined with the qualities of nitinol.

For more information: www.cappella-med.com, http://multivu.prnewswire.com/mnr/cappella/41383/

Related Content

The TIDES-ACS results show us that the Optimax stent is noninferior in patients with acute coronary syndrome compared to Synergy.

The presentation of the ESC late-breaker TIDES-ACS results show us that the Optimax stent is noninferior in patients with acute coronary syndrome compared to Synergy.

News | Stents| November 24, 2017
November 24, 2017 – During a late-breaking session at the European Society of Cardiology (ESC) 2017 meeting, presente
News | Stents| November 10, 2017
Cordis, a Cardinal Health company, recently unveiled a comprehensive interventional cardiology portfolio, which now...
OCT comparison between the Combo vs. Xience stents in the HARMONEE study.

OCT comparison between the Combo vs. Xience stents in the HARMONEE study.

Feature | Stents| November 08, 2017
November 8, 2017 – New results from the HARMONEE Japan/U.S.
FDA Approves COBRA REDUCE Trial of 14-Day DAPT With CeloNova Stent
News | Stents| October 27, 2017
CeloNova BioSciences Inc. announced the U.S. Food and Drug Administration (FDA) approved expansion of CeloNova's...
CeloNova Cobra Pzf stent
Technology | Stents| March 02, 2017
March 2, 2017 — The U.S. Food and Drug Administration (FDA) cleared CeloNova BioSciences Inc.
OCT, intravascular imaging, stent, good stent apposition on vessel wall, TRANSFORM-OCT study

An OCT image showing good stent strut apposition against the vessel wall.

News | Stents| January 13, 2017
January 13, 2017 — Results from TRANSFORM-OCT, a prospective, randomized trial using optical coherence tomography (OC
EXCEL Trial, TCT 2016, drug-eluting stents, CABG, surgery left main heart disease, LMCAD

Gregg W. Stone, M.D., presenting the EXCEL data at TCT 2016 during a standing room only late-breaking trial session.

Feature | Stents| January 12, 2017 | Dave Fornell
The biggest news from the 2016 Transcatheter Cardiovascular Therapeutics (TCT) meeting this past fall was the results
Biotronik's Osiro stent, prison IV trial

Biotronik's Osiro ultra-thin strut, sirolimus-eluting stent.

News | Stents| November 09, 2016
November 9, 2016 – Results from a randomized, multicenter trial failed to show non-inferiority of hybrid, ultra-thin
OCT stent strut coverage

OCT imaging showing neointimal tissue coverage of metallic stent struts.

News | Stents| November 07, 2016
November 7, 2016 – Results from TRANSFORM-OCT, a prospective, randomized trial using optical coherence tomography (OC
biosensors Biofreedom stent
News | Stents| November 07, 2016
November 7, 2016 – The two-year results from LEADERS FREE, the first randomized clinical trial dedicated to high blee
Overlay Init